Table 1.
Results of immunotherapy in clinical trials
| Strategy | Disease | Response | Reference |
|---|---|---|---|
| Monoclonal antibodies | |||
| CD30; brentuximab vedotin | ALCL | ORR 86% (CR 57%) | Pro, JCO 2012 |
| PTCL, AITL | ORR 41%(PTCL), 54%(AITL) | Horwitz, Blood 2014 | |
| Prince, Lancet 2017 | |||
| CD30+ CTCL | TTNT 14m (BV) vs 6m (PC) | Horwitz, Blood 2017 | |
| CD52; alemtuzumab | PTCL | ORR 36% (CR 21%) | Enblad 2004 |
| MF/SS | ORR 55% (CR 32%) | Lundin, Blood 2003 | |
| T-PLL | ORR 90%, med. OS 17 – 33 mo | Dearden, Blood 2001 | |
| CCR4; mogamulizumab | ATLL | ORR 50%, med. PFS 5.2 mo | Ishida, JCO 2012 |
| CCR4+ PTCL/CTCL | ORR 35%, med. PFS 3 mo | Ogura, JCO 2014 | |
| CTCL | ORR 28%, PFS 7.7 mo | Kim, Blood 2017 | |
| CD38; daratumumab | ENKT | NA-ongoing | NCT02927925 |
| CD38; isatuximab | T-ALL | Closed-no response | NCT02999633 |
| CD25; camidanlumab tesirine (ADCT301) | PTCL | ORR 33% (all PR) | Horwitz, Blood 2017 |
| CD30/CD16A; bispecific (AFM13) | CD30+ CTCL | NA-ongoing | NCT03192202 |
| Checkpoint inhibition | |||
| pembrolizumab | ENKL | ORR 100% (5/7 CR) | Kwong, Blood 2017 |
| MF/SS | ORR 38% (1/8 CR) | Khodadoust, Blood 2016 | |
| nivolumab | PTCL | ORR 40% (all PR) | Lesokhin, JCO 2016 |
| ATLL | Closed-disease progression | NCT02631746 | |
| BV + nivolumab | CD30+ PTCL, CTCL | NA-ongoing | NCT02581631 |
| Macrophages activation | |||
| - CD47 Hu5F9-G4 | CTCL, PTCL | NA-ongoing | NCT02216409 |
| - CD47 CC-90002 | TCL | NA-ongoing | NCT02663518 |
| - CD47 TTI-621 | TCL | NA-ongoing | NCT03013218 |
| EBV-CTLs | EBV+ ENKL in CR after RT | 4/6 maintained CR | Bollard, JCO 2014 |
| EBV+ ENKL and PTCL active disease | 4/7 ORR (3 CR) |